Midazolam 3 mg (DrugBank: Midazolam)
11 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
2 | Amyotrophic lateral sclerosis | 0 |
3 | Spinal muscular atrophy | 0 |
6 | Parkinson disease | 0 |
13 | Multiple sclerosis/Neuromyelitis optica | 0 |
21 | Mitochondrial disease | 0 |
46 | Malignant rheumatoid arthritis | 0 |
70 | Spinal stenosis | 0 |
96 | Crohn disease | 1 |
97 | Ulcerative colitis | 0 |
231 | Alpha-1-antitrypsin deficiency | 0 |
298 | Hereditary pancreatitis | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01489943 (ClinicalTrials.gov) | September 19, 2011 | 1/12/2011 | A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects | A Single Centre, Single Sequence, Open-Label, Repeat-Dose Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects | Crohn's Disease | Drug: GSK1605786 500 mg;Drug: Midazolam 3 mg;Drug: Pioglitazone 15 mg;Drug: Omeprazole 40 mg;Drug: Rosuvastatin 10 mg | GlaxoSmithKline | NULL | Completed | 18 Years | 55 Years | All | 24 | Phase 1 | United States |